Achieve Life Sciences (ACHV) Cash & Current Investments (2010 - 2026)

Achieve Life Sciences has disclosed Cash & Current Investments across 17 years of filings, most recently posting $30.5 million for Q1 2026.

• Quarterly Cash & Current Investments fell 8.79% year-over-year to $30.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.5 million (down 8.79% YoY) and the FY2025 annual result came in at $36.4 million, up 5.95% from the prior year.
• Cash & Current Investments slipped to $30.5 million in Q1 2026, from $36.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $107.9 million in Q2 2024 and troughed at $12.8 million in Q1 2023.
• A 5-year average of $40.1 million and a median of $33.4 million in 2025 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 64.85% — and 2024, when it surged 420.4%.
• Tracing ACHV's Cash & Current Investments over 5 years: stood at $22.8 million in 2022, then tumbled by 37.37% to $14.3 million in 2023, then soared by 141.09% to $34.4 million in 2024, then increased by 5.95% to $36.4 million in 2025, then fell by 16.24% to $30.5 million in 2026.
• Business Quant data shows ACHV's Cash & Current Investments at $30.5 million in Q1 2026, $36.4 million in Q4 2025, and $64.3 million in Q3 2025.